Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

Arthritis Research and Therapy

Volumn 8, Issue 6, 2006, Pages

  Vallerskog, Therese ^a   Heimbürger, Mikael ^a   Gunnarsson, Iva ^a   Zhou, Wei ^a   Wahren Herlenius, Marie ^a   Trollmo, Christina ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 70350517490     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2076     Document Type: Article

References (39)

1. Eisenberg R: Update on rituximab. Ann Rheum Dis 2005, 64(Suppl 4):iV55-57.
2. Mackay F, SchAeider P, Rennert P, Browning J: BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21 231-264.
3. Ng LG, Mackay CR, MaLkay F: The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 2005, 42:763-772.
4. Schneider P: The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005, 17:282-289.
5. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, et al.: Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005, 201:1375-1383.
6. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML: Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003, 198:937-945.
7. Dillon SR, Gross JAN Ansell SM, Novak AJ: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006, 5:235-246.
8. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006, 107:4540-4548.
9. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, et al.: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 2004, 104 2247-2253.
10. He B, Raab-Traub N, Casali P, Cerutti A: EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003, 171:5215-5224.
11. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A: Lymphoma B cells evade apoptosis through the TNF family members BAFF/ BLyS and APRIL. J Immunol 2004, 172:3268-3279.
12. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations Arthritis Rheum 2003, 48:3475-3486.
13. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, Weyand CM: BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092.
14. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K: Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005, 25:189-201.
15. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
16. Szodoray P, Jonsson R: The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol 2005, 62:421-428.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
18. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmstrom V, Trollmo C: Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol in press.
19. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006, 54:723-732.
20. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Leguern V, Aouba A, Jean S, et al.: Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis in press.
21. Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
22. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
23. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
24. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, Brink R, Mackay F, Hodgkin PD, Tangye SG: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297.
25. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-98.
26. Kalled SL: Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006, 18:290-296.
27. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM: Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1096-1103.
28. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, Harada M, Horiuchi T: Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1065-1067.
29. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982-992.
30. Ronnblom L, Alm GV: Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003, 5:68-75.
31. Beebe AM, Cua DJ, de Waal Malefyt R: The role of interleukin-10 in autoimmune disease: Systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 2002, 13 403-412.
32. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, et al.: The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106:1021-1030.
33. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ: Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005, 174:864-870.
34. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
35. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X: Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: Insights into a new regulating system of BAFF production. Ann Rheum Dis in press.
36. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
37. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP: Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006, 118:281-292.
38. Zintzaras E, Voulgarelis M, Moutsopoulos HM: The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 2005, 165:2337-2344.
39. Huard B, Schneider P, Mauri D, Tschopp J, French LE: T cell costimulation by the TNF ligand BAFF. J Immunol 2001, 167 6225-6231.